Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain

详细信息    查看全文

• 作者：Chantal Kuhn^a ; Rafael M. Rezende^a ; Andre Pires da Cunha^a ; Fabrice Valette^b ; ^c ; Francisco J. Quintana^a ; ^b ; Lucienne Chatenoud^c ; ^d ; Howard L. Weiner^a ; ^{hweiner@rics.bwh.harvard.edu}
• 关键词：Autoimmune diabetes ; Immunotherapy ; Mucosal tolerance ; CD3 monoclonal antibody ; NOD ; Treg
• 刊名：Journal of Autoimmunity
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：76
• 期：Complete
• 页码：115-122
• 全文大小：1348 K
• 卷排序：76

文摘

Mucosal monoclonal CD3 antibody (CD3 mAb) protects NOD mice from diabetes. Oral administration of CD3 mAb decreases diabetogenicity of effector T cells. Oral CD3 mAb increases the number and function of regulatory T cells.